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Sirolimus-Eluting and Paclitaxel-Eluting Stents
A Subgroup Analysis of the SIRTAX Trial
Mario Togni, MD,* Stéphanie Eber, BA,* Jeannette Widmer, BA,* Michael Billinger, MD,*
Peter Wenaweser, MD,* Stéphane Cook, MD,* Rolf Vogel, MD, PHD,* Christian Seiler, MD, FACC,*
Franz R. Eberli, MD,‡ Willibald Maier, MD,‡ Roberto Corti, MD,‡ Marco Roffi, MD,‡
Thomas F. Lüscher, MD,‡ Ali Garachemani, MD,* Otto M. Hess, MD, FACC,* Simon Wandel, MS,†
Bernhard Meier, MD, FACC,* Peter Jüni, MD,† Stephan Windecker, MD*
Bern and Zurich, Switzerland
Objectives We assessed the impact of vessel size on angiographic and long-term clinical outcome after percutaneous
coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) within a
randomized trial (SIRTAX [Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for Coronary
Revascularization]).
Background Percutaneous coronary intervention in small-vessel disease is associated with an increased risk of major adverse
cardiac events (MACE).
Methods A total of 1,012 patients were randomly assigned to treatment with SES (n  503) or PES (n  509). A strati-
fied analysis of angiographic and clinical outcome was performed up to 2 years after PCI according to size of the
treated vessel (reference vessel diameter 2.75 vs. 2.75 mm).
Results Of 1,012 patients, 370 patients (37%) with 495 lesions underwent stent implantation in small vessels only, 504
patients (50%) with 613 lesions in large vessels only, and 138 patients (14%) with 301 lesions in both small
and large vessels (mixed). In patients with small-vessel stents, SES reduced MACE by 55% (10.4% vs. 21.4%;
p  0.004), mainly driven by a 69% reduction of target lesion revascularization (TLR) (6.0% vs. 17.7%; p 
0.001) compared with PES at 2 years. In patients with large- and mixed-vessel stents, rates of MACE (large:
10.4% vs. 13.1%; p  0.33; mixed: 16.7% vs. 18.0%; p  0.83) and TLR (large: 6.9% vs. 8.6%; p  0.47; mixed:
16.7% vs. 15.4%; p  0.86) were similar for SES and PES. There were no significant differences with respect to
death and myocardial infarction between the 3 groups.
Conclusions Compared with PES, SES more effectively reduced MACE and TLR in small-vessel disease. Differences between
SES and PES appear less pronounced in patients with large- and mixed-vessel disease. (The SIRTAX trial; http://
clinicaltrials.gov/ct/show/NCT00297661?order1; NCT00297661). (J Am Coll Cardiol 2007;50:1123–31)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.015r
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atherosclerosis of small coronary arteries remains a major
hallenge to revascularization procedures, because coro-
ary artery bypass grafting is limited by high rates of
echnical failure (1), and percutaneous coronary interven-
ions (PCI) are associated with an increased risk of
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niversity Hospital Bern, Switzerland; and the ‡Department of Cardiology, Univer-
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ccepted June 25, 2007.estenosis and adverse outcome (2). Stent implantation
esults in arterial injury, initiating a vasculoproliferative
ascade with smooth muscle cell proliferation and migra-
ion resulting in neointimal hyperplasia. The amount of
eointimal hyperplasia is largely independent of vessel
ize and thus late luminal loss, an angiographic measure
f neointimal hyperplasia, is similar across a wide range
f vessel diameters (3,4). Accordingly, small vessels are
ore prone to restenosis than larger vessels, because they
re less able to accommodate neointimal tissue without
ompromising blood flow (5).
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Drug-Eluting Stents and Vessel Size September 18, 2007:1123–31Results of randomized trials
and observational studies com-
paring bare-metal stents with
balloon angioplasty revealed con-
flicting results and only modest
superiority of bare-metal stents
in patients with small-vessel dis-
ease (6–9). Drug-eluting stents
(DES) with site-specific deliv-
ery of therapeutic agents reduce
neointimal hyperplasia more ef-
fectively and have been shown
to improve clinical and angio-
graphic measures of restenosis
compared with bare-metal stents
(10–12). In direct head-to-head
comparisons, sirolimus-eluting
tents (SES) consistently showed lower late luminal loss
ompared with paclitaxel-eluting stents (PES) (13,14). Al-
hough late luminal loss has been proposed as a robust
arker for discriminating DES (15), its impact on clinical
utcomes, such as target lesion revascularization (TLR),
emains controversial, particularly in the low range of late
oss typical for DES.
The SIRTAX (Sirolimus-Eluting Stent Compared
ith Paclitaxel-Eluting Stent for Coronary Revascular-
zation) trial was a randomized controlled trial directly
omparing the safety and efficacy of SES and PES in an
all comers” population undergoing PCI (14). In the
verall population, SES provided lower late luminal loss,
hich translated into lower rates of clinical and angio-
raphic restenosis. The objective of the present analysis
as to evaluate the long-term clinical outcome based on
n extended follow-up of 2 years and angiographic result
f patients stratified according to vessel size, with the
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Small Vessels Only
SES PES
Patients, n 183 187
Age 65 yrs, n (%) 83 (45.4) 94 (50.3)
Males, n (%) 132 (72.1) 145 (77.5)
Diabetes mellitus, n (%) 37 (20.2) 35 (18.7)
Hypertension, n (%) 113 (61.8) 127 (67.9)
Hyperlipidemia, n (%) 119 (65.0) 107 (57.2)
Current smoking, n (%) 67 (36.6) 65 (34.8)
Previous MI, n (%) 57 (31.2) 62 (33.2)
Stable angina pectoris, n (%) 105 (57.4) 94 (50.3)
Acute coronary syndromes, n (%) 78 (42.6) 93 (49.7)
Unstable angina, n (%) 16 (8.7) 12 (6.4)
Non–ST-segment elevation MI, n (%) 34 (18.6) 45 (24.1)
ST-segment elevation MI, n (%) 28 (15.3) 36 (19.3)
Multivessel disease, n (%) 120 (65.6) 111 (59.4)
The p values relate to differences between the 3 groups of patients: 1) patients who underwent s
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationho underwent stent implantation in both small and large vessels.
MI  myocardial infarction; PES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.ypothesis that differences in outcome should be partic-
larly pronounced in patients with small-vessel as op-
osed to large-vessel disease.
ethods
tudy population. The SIRTAX trial was a prospective
bserver-blind randomized controlled study comparing
afety and efficacy of SES and PES in 1,012 patients
ndergoing PCI (14). Eligible patients had a history of
table angina or acute coronary syndrome and presented
ith at least 1 lesion with a diameter stenosis 50% in a
essel with a reference vessel diameter (RVD) between 2.25
nd 4.00 mm suitable for stent implantation. There were no
imitations on the number of treated lesions and vessels or
n lesion length. Prespecified exclusion criteria were known
llergy to aspirin, thienopyridines, stainless steel, sirolimus,
aclitaxel, or contrast agents; participation in another cor-
nary device study; and terminal illness. The study complied
ith the Declaration of Helsinki regarding investigations in
umans and was approved by the institutional ethics com-
ittees at the University Hospitals of Bern and Zurich,
witzerland. All patients provided written informed con-
ent. There was no industry involvement in design, conduct,
r analysis of the study.
andomization and coronary stent procedure. Random-
zation was concealed using sealed, opaque, and sequentially
umbered envelopes. The allocation schedule was based on
omputer-generated random numbers, stratified according
o trial center, and blocked, with block lengths of 6 and 10
aried randomly. Patients were randomly assigned on a 1:1
asis to treatment with SES (Cypher, Cordis, Miami Lakes,
lorida), or PES (Taxus, Boston Scientific, Natick, Massa-
husetts). The SES were available in diameters of 2.25 to
.50 mm and in lengths of 8 to 33 mm. The PES were
Large Vessels Only Small and Large Vessels
p Value*ES PES SES PES
60 244 60 78
(40.0) 102 (41.8) 30 (50.0) 29 (37.2) 0.12
(80.8) 190 (77.9) 40 (66.7) 64 (82.1) 0.25
(19.6) 43 (17.6) 20 (33.3) 15 (19.2) 0.21
(55.8) 144 (59.0) 44 (73.3) 49 (62.8) 0.02
(58.5) 142 (58.2) 34 (56.7) 43 (55.1) 0.51
(37.3) 88 (36.1) 20 (33.3) 28 (35.9) 0.90
(27.3) 65 (26.6) 17 (28.3) 25 (32.1) 0.24
(42.7) 111 (45.5) 30 (50.0) 41 (52.6) 0.01
(57.3) 133 (54.5) 30 (50.0) 37 (47.4) 0.002
(3.9) 13 (5.3) 2 (3.3) 5 (6.4)
(23.5) 59 (24.2) 17 (28.3) 19 (24.4)
(30.0) 61 (25.0) 11 (18.3) 13 (16.7)
(50.0) 125 (51.2) 50 (83.3) 66 (84.6) 0.001
plantation in small vessels only; 2) patients with treatment of large vessels only; and 3) patientsS
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September 18, 2007:1123–31 Drug-Eluting Stents and Vessel Sizevailable in diameters of 2.25 to 3.50 mm and in lengths of
to 32 mm. All interventions were performed according to
urrent practice guidelines for PCI. No mixture of DES was
llowed within a given patient. After the procedure, all
atients were advised to maintain aspirin lifelong, and
lopidogrel therapy was prescribed for 12 months.
aseline Characteristics of Lesions
Table 2 Baseline Characteristics of Lesions
Small Vessels Only
SES PES
Lesions, n 249 246
Target lesion coronary artery, n (%)
Left main 2 (0.8) 2 (0.8)
Left anterior descending 137 (55.0) 130 (52.9)
Left circumflex 77 (30.9) 65 (26.4)
Right 32 (12.9) 45 (18.3)
Bypass graft 1 (0.4) 4 (1.6)
ACC/AHA lesion class, n (%)
A 57 (22.9) 47 (19.1)
B1 98 (39.4) 90 (36.6)
B2 65 (26.1) 65 (26.4)
C 29 (11.7) 44 (17.9)
Angiographic measurements
Lesion length (mm SD) 11.67 6.40 11.97 7.18
Reference vessel diameter (mm  SD) 2.46 0.20 2.46 0.23
Minimal lumen diameter (mm  SD) 0.46 0.35 0.43 0.33
Stenosis (% lumen diameter  SD) 81.51 13.76 82.54 13.53
The p values relate to differences between the 3 groups of patients: 1) patients who underwent s
ho underwent stent implantation in both, small and large vessels.
ACC  American College of Cardiology; AHA  American Heart Association; other abbreviation
rocedural Results
Table 3 Procedural Results
Small Vessels Only
SES PES SE
Lesions, n 249 246 31
Procedures
Lesions treated per
patient (n  SD)
1.4 0.6 1.3 0.6 1.2
Stents per lesion (n SD) 1.1 0.4 1.2 0.5 1.1
Minimal stent
diameter (mm SD)
2.6 0.2 2.6 0.2 3.1
Stent length per
lesion (mm SD)
18.0 8.5 20.3 11.9 19.4
Maximal
pressure (atm SD)
13.9 3.1 13.5 2.8 14.9
Angiographic results
Final minimal lumen
diameter (mm  SD)
In-stent 2.36 0.21 2.41 0.22 2.91
In-segment 2.26 0.27 2.31 0.27 2.82
Final stenosis (% of lumen
diameter SD)
In-stent 6.64 4.48 5.81 4.19 7.69
In-segment 8.87 7.06 7.82 6.63 8.54
Acute gain (mm SD)
In-stent 1.89 0.36 1.98 0.38 2.35
In-segment 1.79 0.40 1.88 0.42 2.34alues are mean  standard deviation. *The p values for interaction relate to differences between the 3
Abbreviations as in Table 1.tudy end points and definitions. Adverse events were
ssessed in the hospital, at 1, 6, and 9 months, and at 1 and
years. An independent clinical events committee unaware
f the patients’ treatment assignments adjudicated all end
oints. Patients were asked to return for angiographic
ollow-up study at 8 months.
Large Vessels Only Small and Large Vessels
p Value*SES PES SES PES
314 299 131 170
0.001
7 (2.2) 7 (2.3) 2 (1.5) 2 (1.2)
5 (39.8) 120 (40.1) 62 (47.3) 73 (42.9)
7 (11.8) 41 (13.7) 25 (19.1) 33 (19.4)
5 (43.0) 125 (41.8) 42 (32.1) 59 (34.7)
0 (3.2) 6 (2.0) 0 (0.0) 3 (1.8)
0.11
3 (16.9) 64 (21.4) 21 (16.0) 43 (25.3)
9 (44.3) 147 (49.2) 63 (48.1) 70 (41.2)
7 (24.5) 62 (20.7) 32 (24.4) 31 (18.2)
5 (14.3) 26 (8.7) 15 (11.5) 26 (15.3)
3 7.06 12.61 7.14 12.07 8.05 12.62 7.21 0.56
3 0.26 3.16 0.29 2.78 0.36 2.75 0.40 0.001
5 0.51 0.60 0.48 0.59 0.45 0.57 0.42 0.001
5 15.95 81.29 14.80 79.15 15.33 79.13 14.67 0.01
plantation in small vessels only; 2) patients with treatment of large vessels only; and 3) patients
Table 1.
Vessels Only Small and Large Vessels
p Value
for Interaction*PES SES PES
299 131 170
1.2 0.5 2.2 0.4 2.2 0.4 0.65
1.1 0.4 1.1 0.4 1.1 0.4 0.71
3.1 0.3 2.8 0.3 2.8 0.4 0.35
18.5 10.4 18.3 10.1 17.6 8.9 0.03
14.6 3.0 14.0 2.8 13.8 2.6 0.89
2.93 0.34 2.60 0.31 2.61 0.36 0.67
2.93 0.32 2.51 0.37 2.50 0.44 0.16
7.21 6.44 7.54 4.99 7.48 5.17 0.61
8.13 5.75 9.89 8.74 9.54 7.51 0.83
2.34 0.54 2.01 0.49 2.04 0.50 0.22
2.34 0.57 1.95 0.53 1.97 0.54 0.5112
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Drug-Eluting Stents and Vessel Size September 18, 2007:1123–31The prespecified primary end point was a composite of
ajor adverse cardiac events (MACE) up to 9 months,
efined as cardiac death, myocardial infarction, or ischemia-
riven revascularization of the target lesion (TLR). Second-
ry end points included ischemia-driven TLR, target vessel
evascularization, or target vessel failure. The latter two were
onsidered to be driven by ischemia if the stenosis of the target
esion or vessel was50% on the basis of quantitative coronary
ngiography in the presence of ischemic signs or symptoms or
f there was a stenosis of 70% in the absence of ischemic
igns or symptoms. Target lesion revascularization was
efined as a repeated revascularization based on a stenosis
ithin the stent or within the 5-mm borders proximal or
istal to the stent. The diagnosis of periprocedural myocar-
ial infarction was established whenever new Q waves of at
east 0.4 seconds’ duration in at least 2 contiguous leads
ppeared on the electrocardiogram with an elevated creatine
inase-MB fraction level or, in the absence of pathologic Q
aves, by an elevation in creatine kinase levels to more than
wice the upper limit of normal with an elevated creatine
inase-MB or troponin I level. Stent thrombosis was
efined as an acute coronary syndrome with angiographic
ocumentation of either target vessel occlusion or thrombus
ithin or adjacent to the previously successfully stented
egment.
uantitative coronary angiography. Coronary angio-
rams were digitally recorded at baseline, immediately after
tent implantation, and at follow-up and were assessed at
he angiographic core laboratory of the University Hospital
ern. Angiogram readers were unaware of the type of stent
mplanted. Digital angiograms were analyzed with the use
f an automated edge-detection system (CAAS II, Pie
edical Imaging, Maastricht, the Netherlands). The in-
raobserver and interobserver reliabilities of the quantitative
easurements have been reported previously (16).
Quantitative measurements included the RVD, the min-
mal luminal diameter, percentage diameter stenosis, and
ate luminal loss. Binary restenosis was defined as stenosis
50% in the target lesion at angiographic follow-up. All
ngiographic measurements of the target lesion were ob-
ained in the stent and the areas within 5 mm proximal and
istal to the stent edge.
tatistical analysis. A stratified analysis of clinical and
ngiographic outcomes, which was specified after comple-
ion of patient recruitment, was performed according to
essel size. We used quantitative coronary angiography to
etermine the RVD. Patients, who underwent stent im-
lantation only in lesions with an RVD 2.75 mm were
ategorized as having undergone treatment of small vessels.
onversely, patients who underwent stent implantation
nly in lesions with an RVD2.75 mm were categorized as
aving undergone treatment of large vessels. Patients with
tent implantations in both small and large vessels were
lassified as “mixed.” All randomized patients were included
n the analysis of primary and secondary clinical outcomes inthe groups to which they were originally allocated toT
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September 18, 2007:1123–31 Drug-Eluting Stents and Vessel Sizeintention-to-treat principle). Analyses of outcomes of the
ngiographic substudy were restricted to lesions from pa-
ients who attended follow-up angiography. We used a Cox
roportional hazards model to compare clinical outcomes
Figure 1 Kaplan-Meier Cumulative Event
Curves of TLR Stratified for Stent Type
(A) Small vessels only; (B) large vessels only; (C) both small
and large vessels (mixed). TLR  target lesion revascularization.etween the groups. To determine whether there was an vnteraction between treatment effect and type of vessel
isease, we used likelihood ratio tests. Stratified analyses
equire about 4 times as many events to detect treatment by
atient interactions of a magnitude of the overall treatment
ffect (17). The trial was designed to detect a relative risk of
.5 of MACE in the primary analysis of all patients at 9
onths, when 86 events had occurred, with a power of 90%
14). A post hoc power analysis based on 142 MACE that
ad occurred at up to 2 years indicated that the trial would
ave a power of 44% to detect an interaction between
reatment and vessel size of a similar magnitude.
The differences in treatment effects between small- and
arge-vessel disease were driven by percutaneous TLR. For
his end point we performed an additional series of sensi-
ivity analyses: in addition to the term for the treatment by
essel size interaction, we included terms for interactions
etween treatment and age, gender, diabetes, hypertension,
nd acute coronary syndrome and determined whether the
reatment by vessel size interaction was affected by the
nclusion of these additional interaction terms. Analyses
ere performed in Stata Version 9.2 (Stata, College Station,
exas); p values are 2-sided.
esults
aseline clinical, angiographic, and procedural data. A
otal of 1,012 patients were randomly assigned to treatment
ith SES (503 patients with 694 lesions) and PES (509
atients with 715 lesions); 370 patients (37%) with 495
esions had only small-vessel (RVD 2.75 mm), 504
atients (50%) with 613 lesions had only large-vessel
RVD2.75 mm), and 138 patients (14%) with 301 lesions
ad small- and large-vessel (mixed) disease.
Baseline clinical and angiographic variables for all 3
roups are summarized in Tables 1 and 2. There were
ignificant differences in the prevalence of hypertension
p  0.02) and stable angina pectoris (p  0.01). Among
atients with acute coronary syndromes, ST-segment ele-
ation myocardial infarctions were more frequent in those
ith stent implantations in large vessels only (p  0.002).
he incidence of multivessel disease was highest in the
ixed-vessel disease group (p  0.001). Target lesion
nvolvement of the left anterior descending and circumflex
oronary arteries was more frequent in the small-vessel group,
hereas the right coronary artery was more frequently treated
n the large-vessel population (Table 2). Lesion length and
egree of stenosis were similar, whereas minimal lumen
iameter and RVD differed among the 3 groups.
Procedural results are presented in Table 3. The number
f lesions treated per patient was higher in the mixed group
2.2  0.4), compared with small (1.4  0.6) and large
1.2  0.5; p  0.001) vessels only. Stents implanted into
arge vessels were deployed at higher mean pressure than
hose implanted into small vessels (p  0.001). With p
alues for interaction of 0.16, there was little evidence for
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Drug-Eluting Stents and Vessel Size September 18, 2007:1123–31ifferences in procedural outcome between SES and PES in
ll 3 groups.
linical outcome. Clinical events at 2-year follow-up
tratified for vessel size are listed in Table 4. In patients with
mall-vessel disease, SES more effectively reduced MACE
han PES at 2 years (10.4% vs. 21.4%, respectively, hazard
atio [HR] 0.45, 95% confidence interval [CI] 0.26 to 0.78;
 0.004). This difference was largely driven by a 69%
eduction in the risk of TLR in favor of SES (6.0% vs.
7.7%, HR 0.31, 95% CI 0.16 to 0.62; p  0.001)
Fig. 1A). There were no significant differences between
ES and PES in small-vessel disease patients with respect to
eath, cardiac death, or myocardial infarction at up to 2
ears of follow-up.
Rates of MACE (10.4% vs. 13.1%, respectively, HR
.78, 95% CI 0.46 to 1.29; p  0.33) and TLR (6.9% vs.
.6%, respectively, HR 0.79, 95% CI 0.42 to 1.49; p 0.47)
t 2 years were similar for SES and PES in patients with
arge-vessel disease (Fig. 1B). Similarly, there were no
ignificant differences with respect to death, cardiac death,
r myocardial infarction at up to 2 years of follow-up. In
atients with both small- and large-vessel disease (mixed
roup), rates of MACE (16.7% vs. 18.0%, respectively, HR
.91, 95% CI 0.41 to 2.05; p  0.83) and TLR (16.7% vs.
5.4%, respectively, HR 1.08, 95% CI 0.47 to 2.50; p 
.86) were comparable for SES and PES at 2 years (Fig.
C). Differences between small- and large-vessel disease
ere driven by percutaneous TLR, and tests for interaction
etween treatment effect and vessel size reached formal
tatistical significance only for this outcome. When includ-
ng additional terms for age, gender, diabetes, hypertension,
ngiographic Follow-Up Results at 8 Months Stratified by Vessel S
Table 5 Angiographic Follow-Up Results at 8 Months Stratified
Small Vessels Only
SES PES
Difference
(95% CI)
Lesions (n) 134 136
Minimal lumen
diameter
(mm  SD)
In-stent 2.29 0.28 2.15 0.55 0.15 (0.04 to 0.26)
In-segment 2.14 0.39 1.94 0.64 0.20 (0.07 to 0.34)
Stenosis
(% of lumen
diameter SD)
In-stent 8.40 8.36 14.46 20.53 6.06 (9.97 to2.1
In-segment 13.36 13.71 21.96 24.27 8.59 (13.6 to3.6
Late loss (mm SD)
In-stent 0.08 0.18 0.26 0.49 0.18 (0.28 to0.0
In-segment 0.12 0.30 0.37 0.60 0.25 (0.37 to0.1
Binary restenosis (%)
In-stent 1.5 8.8 7.3 (13.3 to1.3
In-segment 4.5 16.2 11.7 (19.4 to4.0
alues are mean standard deviation. *The p values relate to differences between patients treate
r percentage between the 3 groups of patients: 1) patients who underwent stent implantation in
mplantation in both small and large vessels.
Abbreviations as in Tables 1 and 4.nd acute coronary syndrome for percutaneous TLR, we 1ound the interaction between treatment and vessel size
naffected (data available on request).
The incidence of stent thrombosis was low and estimates
f hazard ratios imprecise (Table 4). The cumulative fre-
uency of stent thrombosis at 2 years amounted to 2.2% for
ES and 2.7% for PES in small-vessel disease (HR 0.81,
5% CI 0.22 to 3.01; p  0.75), 1.9% and 3.3%, respec-
ively, in large-vessel disease (HR 0.58, 95% CI 0.19 to
.78; p  0.35), and 5.0% and 1.3%, respectively, in the
ixed group (HR 3.93, 95% CI 0.41 to 37.8; p  0.24).
ngiographic results. Angiographic follow-up at 8
onths was obtained in 200 of 370 patients with small-
essel disease (54%), 252 of 504 patients with large-vessel
isease (50%), and 68 of 138 patients with mixed dis-
ase (49%) (Table 5). Patients undergoing angiographic
ollow-up were younger (p  0.001), less likely to have
iabetes (p  0.04) or hypertension (p  0.04), and more
ikely to be male (p  0.004) and to have experienced chest
ain (p  0.01). There was a difference in in-stent (2.29 
.28 mm vs. 2.15  0.55 mm; p  0.01) and in-segment
2.14  0.39 mm vs. 1.94  0.64 mm; p  0.004) minimal
umen diameter in favor of SES in small-vessel disease,
hereas results were similar in large- and mixed-vessel
isease. The SES more effectively reduced in-stent late
uminal loss in all 3 subgroups, but differences were more
ronounced in the small-vessel group (0.08  0.18 mm vs.
.26  0.49 mm; p  0.001). Although the rate of
n-segment binary restenosis was significantly lower with
ES (4.5%) than PES (16.2%; p  0.003) in small-vessel
isease, rates were similar in large-vessel (SES 7.6%, PES
.0%; p  0.85) and mixed-vessel disease (SES 9.1%, PES
essel Size
Large Vessels Only
p
Value* SES PES
Difference
(95% CI)
p
Value*
159 143
0.01 2.75 0.51 2.77 0.61 0.02 (0.15 to 0.11) 0.76
0.004 2.60 0.58 2.66 0.66 0.06 (0.20 to 0.08) 0.42
0.003 11.03 14.26 13.06 16.64 2.02 (5.71 to 1.66) 0.28
0.001 15.31 17.24 15.91 18.00 0.59 (4.69 to 3.50) 0.78
0.001 0.15 0.44 0.23 0.48 0.08 (0.19 to 0.03) 0.15
0.001 0.23 0.52 0.28 0.52 0.05 (0.17 to 0.07) 0.41
0.02 3.8 5.6 1.8 (6.6 to 2.9) 0.45
0.003 7.6 7.0 0.6 (5.3 to 6.4) 0.85
ES as opposed to PES for each stratum. The p values for interaction relate to differences in mean
essels only; 2) patients with treatment of large vessels only; and 3) patients who underwent stentize
by V
4)
0)
9)
2)
)
)
d with S
small v2.8%; p  0.55). Tests for interaction between treatment
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September 18, 2007:1123–31 Drug-Eluting Stents and Vessel Sizeffect and vessel size reached formal statistical significance
or in-segment minimal lumen diameter, diameter stenosis,
ate luminal loss, and binary stenosis.
iscussion
he principal findings of this subgroup analysis of the
IRTAX trial stratified by vessel size are as follows:
. Sirolimus-eluting stents more effectively reduce rates of
MACE and TLR in patients with small-vessel disease
(RVD 2.75 mm).
. The therapeutic benefit of SES over PES is maintained
at 2 years’ follow-up.
. Differences in rates of MACE and TLR tend to be less
pronounced in patients with large-vessel and mixed-
vessel disease at 1 and 2 years’ follow-up.
. There are no significant differences between SES and
PES with respect to death, cardiac death, myocardial
infarction, or stent thrombosis in patients with small-,
large-, and mixed-vessel disease at 2 years.
. Sirolimus-eluting stents provide lower late luminal loss,
translating into lower rates of binary restenosis, partic-
ularly in patients with small-vessel disease.
he results of the present study are biologically plausible,
ecause a reduction in luminal diameter by a constant
mount of neointimal hyperplasia results in a proportionally
igher-grade diameter stenosis in small compared with large
essels. Moreover, SES have been invariably shown to afford
ower late luminal loss in all trials with angiographic
ollow-up directly comparing SES and PES (13,14,18–20),
nd late luminal loss is an established marker to discrim-
nate between different stent types (15). However, the
mpact of differences in late luminal loss on clinical
ontinued
Table 5 Continued
Small
SES PES
Lesions (n) 55 94
Minimal lumen
diameter
(mm  SD)
In-stent 2.44 0.58 2.37 0.66
In-segment 2.26 0.65 2.18 0.71
Stenosis
(% of lumen
diameter SD)
In-stent 12.76 17.27 14.98 20.27
In-segment 17.56 20.28 21.18 22.74
Late loss (mm SD)
In-stent 0.15 0.46 0.25 0.52
In-segment 0.24 0.51 0.33 0.54
Binary restenosis (%)
In-stent 5.5 8.5
In-segment 9.1 12.8utcome remains controversial, and the present study eay help to identify patients who derive the greatest benefit
rom SES.
The findings of this subgroup analysis of a large-scale
andomized trial directly comparing SES and PES are
onsistent with previously published data on: 1) indirect
omparisons of SES and PES in small vessels (21–23); 2)
egistry experience comparing SES and PES in small vessels
24); and 3) direct comparison in a dedicated randomized
rial of SES and PES in small vessels (25). Stone et al. (21)
eported relatively high rates of restenosis (31%) and TLR
10.4%) in 108 patients treated with the 2.25-mm diameter
ES in the TAXUS (In-Stent Restenosis Treated With
tent-Based Delivery of Paclitaxel Incorporated in a Slow-
elease Polymer Formulation) V trial. In contrast, Nikolsky
t al. (22) observed lower rates of restenosis (17%) and TLR
4.3%) in a similar patient population of 100 patients treated
ith 2.25-mm diameter SES. Similar results have been
bserved in the SES-SMART (Sirolimus-Eluting Stent
nd a Standard Stent in the Prevention of Restenosis in
mall Coronary Arteries) trial (23) with restenosis and TLR
ates of 10% and 7%, respectively, in SES-treated vessels. In
registry comparison of SES and PES from the Thorax-
enter, Rotterdam, rates of both TLR and MACE were
igher for PES than SES (TLR: 5% vs. 1.4%; p  0.08;
ACE: 17.8% vs. 5.6%; p 0.007) (24). In the REALITY
Prospective Randomized Multi-Center Head-to-Head
omparison of the Sirolimus-Eluting Stent [Cypher] and
he Paclitaxel-Eluting Stent [Taxus]) trial (13), late loss was
ignificantly lower in SES- compared with PES-treated
atients, confirming the results of the present study. How-
ver, the difference in late loss in favor of SES failed to
ranslate into a significant difference regarding binary reste-
osis (SES 9.6% vs. PES 11.1%; p  0.31). This may be
arge Vessels
Difference
(95% CI)
p
Value*
p Value for
Interaction*
0.08 (0.12 to 0.27) 0.43 0.17
0.09 (0.14 to 0.31) 0.44 0.03
2.21 (8.83 to 4.40) 0.51 0.29
3.62 (11.61 to 4.38) 0.37 0.05
0.10 (0.28 to 0.08) 0.26 0.35
0.09 (0.29 to 0.11) 0.39 0.05
3.1 (11.7 to 5.6) 0.49 0.23
3.7 (15.6 to 8.2) 0.55 0.06and Lxplained in part by a significantly lower postprocedural
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Drug-Eluting Stents and Vessel Size September 18, 2007:1123–31n-stent minimal luminal diameter in SES compared with
ES (2.08 vs. 2.16 mm; p  0.001). Accordingly, the more
otent effect of SES in reducing neointimal hyperplasia may
ave been offset in part by the inferior immediate postpro-
edural result.
Finally, a dedicated randomized trial directly compared
ES and PES in a patient population of a size similar to the
resent subgroup analysis and observed significantly lower
ate loss (0.13  0.56 mm vs. 0.34  0.57 mm; p  0.001),
n-segment restenosis (11.4% vs. 19.0%; p  0.047), and
LR (6.6% vs. 14.7%; p  0.008) in SES- compared with
ES-treated patients, respectively (25).
The impact of vessel size on outcome with DES has
ecently been evaluated by Elezi et al. (26). They observed
ower late luminal loss for SES compared with PES in all 3
essel size tertiles, which translated into a lower rate of TLR
n favor of SES (8.6% vs. 16.4%; p  0.002) only in the
owest vessel size tertile (RVD 2.41 mm). In a separate
egistry analysis of predictive factors of restenosis after
mplantation of SES and PES, Kastrati et al. (27) identified
essel size and DES type as strongest predictors of resteno-
is. Thus, results of a classification and regression tree
evealed that rates of TLR were lower for SES than PES
7.8% vs. 15.6%) in vessels smaller than 2.6 mm and similar
7.2% vs. 7.2%) in larger vessels. The present study corrob-
rates the findings of those studies and adds additional
nformation, because the data were derived from a large-
cale randomized trial with adequate concealment of allo-
ation, minimizing the risk of selection bias at study entry
28) and assuring similar patient and lesion characteristics
etween SES- and PES-treated patients. Moreover, regular
ollow-up at predefined intervals provided additional rigor
f data collection and allowed extending the observation
eriod to 2 years.
The frequency of diabetes in the present study tends to be
igher in small-vessel than in large-vessel disease, but is not
s pronounced as reported by Elezi et al. (26), who de-
cribed a higher frequency of diabetes in patients in the
owest vessel size tertile (RVD 2.41 mm). However, the
requency of diabetes in patients was similar in the middle
ertile (RVD 2.41 to 2.84 mm). Differences in RVD
etween diabetic and nondiabetic patients in the TAXUS
V trial (29) and the SIRIUS (Sirolimus-Eluting Stent in
oronary Lesions) trial (30) were only minimal and in
ccordance with our results.
tudy limitations. This is a subgroup analysis of a ran-
omized trial not powered to detect treatment-subgroup
nteractions. It was not prespecified and is therefore explor-
tory in nature. A post hoc power analysis indicated that the
rial would have a power of only 44% to detect a clinically
elevant interaction between treatment and vessel size. Not
urprisingly, the majority of interaction tests did not reach
ormal statistical significance and we cannot exclude that
ome of the observed differences in treatment effects be-
ween small- and large-vessel disease may have occurred by
hance alone. However, the concordance between clinical
snd angiographic results suggests that the observed pattern
ay be real. Irrespective of the results of interaction tests, it
an be concluded that SES is more beneficial than PES in
mall-vessel disease in terms of a reduction of TLR and
ACE. The advantage of SES over PES appears less
ronounced in large- and mixed-vessel disease, and inter-
ction tests indicate that this trend toward a less pronounced
dvantage of SES over PES in large-vessel disease may have
ccurred by chance alone.
The SIRTAX trial was performed in an unselected “all
omers” population, and 138 patients were treated for both
mall- and large-vessel disease (mixed group). These latter
atients were more complex, as evidenced by a higher
revalence of multivessel disease and a nearly 2-fold higher
umber of lesions treated per patient compared with both
he small- and the large-vessel disease groups. Although
verall rates of MACE were similar for SES and PES in the
ixed group, most of the adverse events were related to
mall vessels.
The rate of angiographic follow-up (51%) was low. This
ay have been related to the absence of a financial incentive
nd the broad inclusion criteria, with elderly patients and
hose with comorbid conditions being more reluctant to
ndergo repeat angiography than younger healthier patients
ypically included in angiography trials. Angiographic rou-
ine follow-up is known to increase the rate of TLR, and the
ncomplete angiographic follow-up in the present trial may
ave led to attrition bias (28), potentially resulting in an
verestimation of differences in TLR and MACE between
ES and PES. We consider this unlikely, because the
ifference in MACE in favor of SES was already appar-
nt before the scheduled angiographic follow-up at 6
onths (HR for MACE at 6 months 0.56, 95% CI 0.32
o 0.96; p  0.035).
onclusions
essel size remains an important determinant of adverse
utcome in the DES era. Sirolimus-eluting stents are more
ffective than PES in reducing angiographic and clinical
easures of restenosis. The benefit is particularly pro-
ounced in small vessels less able to accommodate neointi-
al hyperplasia, whereas the selection of a particular DES
ppears less relevant in larger vessels. The observed
herapeutic benefit is likely to apply to newer second-
eneration DES using limus analogues with similar
eductions of late luminal loss but the potential for an
mproved safety profile.
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